Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mindray Medical International

Related MR
Benzinga's Top Downgrades
UPDATE: Morgan Stanley Downgrades Mindray Medical International As Uncertainties Linger

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mindray Medical International (NYSE: MR), and raised its price target from $34.00 to $36.00.

Jefferies noted, “MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential stepback in the margin profile, but in-line non-GAAP EPS. Language regarding deterioration in developed markets, abrupt CEO change, and still unresolved supplier dispute leave lingering questions but overall growth profile still among upper tier.”

Mindray Medical International closed on Tuesday at $31.90.

Latest Ratings for MR

DateFirmActionFromTo
Dec 2014Morgan StanleyDowngradesEqual-weightUnderweight
May 2014JefferiesAssumesHold
May 2014Bank of AmericaDowngradesBuyNeutral

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MR)

Around the Web, We're Loving...

Get Benzinga's Newsletters